Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: February 2010
-
By Sarah Fendrick — The U.S. Patent and Trademark Office has extended the time for public comment for two recent Office initiatives and has extended the period of effectiveness for a third Office initiative. Extension of Period for Comments on Enhancement in the Quality of Patents In December 2009, the USPTO published a notice…
-
February 9, 2010 – Patent Prosecution: Best Practices for Reducing Costs While Improving Patent Quality (Technology Transfer Tactics) – 1:00 – 2:30 PM (EST) February 17-18, 2010 – Biotech & Pharmaceutical Patenting (IIR) – Munich, Germany February 24-25, 2010 – 2nd Expert Forum on ITC Litigation & Enforcement (American Conference Institute) – New York, NY…
-
American Conference Institute (ACI) will be holding its 4th Annual Paragraph IV Disputes conference on April 27-28, 2010 in New York, NY. The conference will allow attendees to: • Identify patents for small molecules and small proteins that may be ripe for a Paragraph IV challenge;• Recognize an ANDA applicant's initial obligations and reevaluate Orange…
-
By Donald Zuhn — In a press conference held earlier today, the Biotechnology Industry Organization (BIO) expressed concern about recommendations to be issued on Friday with a report on gene patents. The report, entitled "Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests," is being issued by the Secretary's…
-
By Suresh Pillai — Settlement Announced in Focalin® Infringement Suit Celgene, Novartis Pharmaceuticals, and Teva Pharmaceuticals have filed three separate stipulations in the U.S. District Court for the District of New Jersey that will, if approved by the Court, put an end to all claims among the parties. The long running dispute stemmed from…
-
By Donald Zuhn — In January, GlaxoSmithKline announced a series of initiatives for developing new medicines to combat diseases that disproportionately affect the world's poorest countries. The initiatives, which comprise GSK's "open innovation" strategy, were outlined in a speech given by GSK Chief Executive Andrew Witty to the Council on Foreign Relations on January…
-
By Donald Zuhn — In a letter sent to Speaker of the House Nancy Pelosi (D-CA), House Majority Leader Steny Hoyer (D-MD), and House Minority Leader John Boehner (R-OH) earlier today, Representatives Mike Michaud (D-ME), Don Manzullo (R-IL), Dana Rohrabacher (R-CA), and Marcy Kaptur (D-OH) urged the House leaders to "remember the importance of…
-
By Kevin E. Noonan — Fifteen hundred years ago everybody knew the Earth was the center of the universe. Five hundred years ago, everybody knew the Earth was flat, and fifteen minutes ago, you knew that humans were alone on this planet. Imagine what you'll know tomorrow. Men in Black (1997) And in 2010,…
Patent Docs 